ESPI Current Report, No. 2/2023, Addendum to Report No. 1/2023 dated 9/01/2023. – Acquisition of a production line for nutraceuticals and dietary supplements in liquid form. MEDIAN POLSKA S.A. (PLMDNPL00013)

10-01-2023 11:48:14 | Current | ESPI | 2/2023

Legal basis
Article 17 (1) MAR – confidential information.
Contents of the report:
The Management Board of Median Polska S.A. with its seat in Myslowice _hereinafter: the Company_ hereby provides additions to ESPI Report No. 1/2023 dated January 9, 2023, in which it announced the acquisition of a line for the production of nutraceuticals and dietary supplements in liquid form.
The Board of Directors hereby indicates that the automatic production line for nutraceuticals and dietary supplements in liquid form, which was acquired and received on January 09, 2023, was purchased for PLN 151,942, to be paid by the Company within 90 days in cash. The Company received a 12-month warranty for the production line. The line was purchased from an entity affiliated with a shareholder holding more than 5% of votes at the Company’s general meeting.
At the same time, the Management Board recalls that this investment will allow the Company to optimize costs and increase production capacity, which will translate into better quality and availability of the offered products. In addition, the line will enable the Company to introduce new products to the market. The Management Board indicates that the new production line will be a beneficial solution for the Company and its customers.

• Piotr Zawadzki- President of the Management Board